PSMO-10 - Antimicrobial resistance: Pharmaceutical innovation during the silent pandemic

Organised by The Australasian Pharmaceutical Science Association


Prof. Andrew McLachlan, University of Sydney, Australia and Mr Andrew Bowskill, Australian Antimicrobial Resistance Network (AAMRNet), Australia


Antimicrobial resistance (AMR) remains one of the greatest challenges to human health, resulting in the loss of approximately 10 million lives globally. Concerns that AMR rose during the COVID-19 pandemic have raised further issues for the pharmaceutical sector. Studies continue to demonstrate an overuse of antibiotics in affected patients, even when not clinically indicated. AMR is also being increasingly identified as responsible for life-threatening complications amongst intensive care patients. This broad ranging symposium will look at pharmaceutical innovations in AMR from policy, scientific and clinical perspectives.




14:30 – 14:35 Session introduction by the chairs
14:35 – 15:00 The antimicrobial landscape — Getting the policy framework right
Mr Andrew Bowskill [MTP Connect], Australian Antimicrobial Resistance Network [AAMRNet], Brisbane, Australia
15:00 – 15:25 How do we replenish the antibiotic pipeline
Prof. Mark Blaskovich, University of Queensland, Australia
15:25 – 15:50 Systems pharmacology approaches to novel antimicrobial development
Dr Gauri Rao, University of North Carolina, United States
15:50 – 16:00 Closing and summary

Learning objectives

  • To understand the current landscape and policy frameworks associated with antimicrobial prescribing and use
  • To describe how systems pharmacology approaches can be exploited to improve the development of novel antimicrobial agents
  • To appreciate how pharmacokinetic-pharmacodynamic principles are employed for optimising antibiotic use

Take home messages

Join this symposium to hear about the latest approaches to tackle antimicrobial resistance from policy frameworks to pharmacokinetic-pharmacodynamic models to improve patient outcomes.